China Resources Pharmaceutical Group Limited (03320.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

5.3x

Market Cap

HKD 27.86B

MomentumView details →

1D Return

+0.57%

YTD Return

−0.34%

RSI (14)

31.1

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

5.3x

Market Cap

HKD 27.86B

RSI (14)

31.1

MomentumView details →

1D Return

+0.57%

YTD Return

−0.34%

ProfitabilityView details →

Gross Margin

16.10%

Net Margin

1.32%

EBITDA Margin

5.65%

ROE (TTM)

12.71%

ROA (TTM)

2.28%

Asset Turnover

1.79x

GrowthView details →

Revenue YoY

+8.80%

EPS YoY

−5.38%

FCF YoY

−19.73%

Revenue CAGR 3Y

+10.37%

EPS CAGR 3Y

+9.39%

EBITDA YoY

+3.86%

EarningsView details →

EPS (Actual)

HKD 0.40

EPS Surprise

−12.48%

Beats (12Q)

0/12

Next Q EPS Est

—

Avg Surprise (4Q)

−12.48%

Rev Surprise

−3.05%

Capital & dividendView details →

Debt/Equity

1.87x

Current Ratio

1.43x

Quick Ratio

1.12x

Div Yield

4.91%

Div Rate

HKD 0.22

Div Growth 1Y

+3.04%

Financials snapshotView financials →

Revenue (TTM)

588.38B

Net Income (TTM)

7.75B

Op. CF (TTM)

—

Next earningsMar 24, 2027 →

Latest newsMore news →

China Resources Pharmaceutical Group Limited advanced its innovative drug pipeline, with a Class 1 antidepressant entering Phase IIb, DC6001 receiving clinical trial approvals in China and the U.S. and FDA Pediatric Rare Disease Designation, and DC7001A filed in China and the U.S.11d ago

China Resources Pharmaceutical reported interim results for the six months ended June 2026, with net profit up 5.3% to RMB 2.187 billion and total revenue up nearly 2% to RMB 134.458 billion.12d ago

Similar companies

达仁堂600329.SH China Medical System Holdings Limited00867.HK ST人福600079.SH The United Laboratories International Holdings Limited03933.HK Zoetis Inc.ZTS 华海药业600521.SH Find similar companies →

Latest newsMore news →

China Resources Pharmaceutical Group Limited advanced its innovative drug pipeline, with a Class 1 antidepressant entering Phase IIb, DC6001 receiving clinical trial approvals in China and the U.S. and FDA Pediatric Rare Disease Designation, and DC7001A filed in China and the U.S.11d ago China Resources Pharmaceutical reported interim results for the six months ended June 2026, with net profit up 5.3% to RMB 2.187 billion and total revenue up nearly 2% to RMB 134.458 billion.12d ago